NWQ Investment Management Company LLC lowered its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 13.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,691 shares of the medical research company’s stock after selling 23,069 shares during the quarter. NWQ Investment Management Company LLC owned approximately 0.50% of Bio-Rad Laboratories worth $47,165,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of BIO. Bodenholm Capital AB purchased a new position in Bio-Rad Laboratories in the 3rd quarter worth about $32,540,000. First Trust Advisors LP increased its stake in Bio-Rad Laboratories by 1,258.0% in the 3rd quarter. First Trust Advisors LP now owns 102,437 shares of the medical research company’s stock worth $32,062,000 after purchasing an additional 94,894 shares in the last quarter. GW&K Investment Management LLC purchased a new position in Bio-Rad Laboratories in the 3rd quarter worth about $20,890,000. Prudential Financial Inc. increased its stake in Bio-Rad Laboratories by 184.8% in the 3rd quarter. Prudential Financial Inc. now owns 77,931 shares of the medical research company’s stock worth $24,392,000 after purchasing an additional 50,565 shares in the last quarter. Finally, Columbus Circle Investors increased its stake in Bio-Rad Laboratories by 54.1% in the 3rd quarter. Columbus Circle Investors now owns 129,183 shares of the medical research company’s stock worth $40,433,000 after purchasing an additional 45,344 shares in the last quarter. 62.37% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have commented on the company. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, November 12th. Barclays decreased their price objective on Bio-Rad Laboratories from $345.00 to $315.00 and set an “equal weight” rating for the company in a research report on Friday, November 2nd. Goldman Sachs Group assumed coverage on Bio-Rad Laboratories in a research report on Wednesday, October 17th. They set a “buy” rating and a $350.00 price objective for the company. Jefferies Financial Group restated a “buy” rating and set a $420.00 price objective on shares of Bio-Rad Laboratories in a research report on Monday, September 24th. Finally, Morgan Stanley assumed coverage on Bio-Rad Laboratories in a research report on Thursday, September 20th. They set an “equal weight” rating and a $335.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $338.43.

NYSE BIO traded down $1.87 during trading on Friday, reaching $261.12. 2,027 shares of the company’s stock were exchanged, compared to its average volume of 186,104. Bio-Rad Laboratories, Inc. has a fifty-two week low of $231.00 and a fifty-two week high of $345.15. The firm has a market capitalization of $7.98 billion, a PE ratio of 63.69, a PEG ratio of 3.24 and a beta of 1.09. The company has a current ratio of 4.49, a quick ratio of 3.16 and a debt-to-equity ratio of 0.09.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, November 1st. The medical research company reported $0.91 EPS for the quarter, missing the Zacks’ consensus estimate of $1.16 by ($0.25). Bio-Rad Laboratories had a return on equity of 3.72% and a net margin of 55.13%. The business had revenue of $545.10 million for the quarter, compared to analyst estimates of $541.23 million. During the same quarter in the previous year, the business posted $0.91 earnings per share. The company’s revenue was up 2.1% compared to the same quarter last year. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 5.47 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/bio-rad-laboratories-inc-bio-shares-sold-by-nwq-investment-management-company-llc/2668464.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Further Reading: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.